Approved Ligands

Product Describtion:Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.Product Application:Dapoxetine is a serotonin reuptake inhibitor used for the

Product Describtion:Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.Product Application:Dapoxetine is a serotonin reuptake inhibitor used for the

Product Describtion:Dapoxetine ((+)-(S)-N,N-dimethyl-(α)-[2(1naphthal enyloxy)ethyl]-benzenemethanamine hydrochloride) possess a similar structure as that of fluoxetine.Product Application:Dapoxetine is a serotonin reuptake inhibitor used for the

InformationDarolutamide (ODM-201) Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K i of 11 nM. Phase 3.TargetsAndrogen receptor 11 nM(Ki)In vitroIn AR-HEK293 cells stably

InformationDarolutamide (ODM-201) Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K i of 11 nM. Phase 3.TargetsAndrogen receptor 11 nM(Ki)In vitroIn AR-HEK293 cells stably

InformationDarolutamide (ODM-201) Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K i of 11 nM. Phase 3.TargetsAndrogen receptor 11 nM(Ki)In vitroIn AR-HEK293 cells stably

InformationDarolutamide (ODM-201) Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K i of 11 nM. Phase 3.TargetsAndrogen receptor 11 nM(Ki)In vitroIn AR-HEK293 cells stably

InformationDarolutamide (ODM-201) Darolutamide (ODM-201, BAY-1841788) is a novel androgen receptor (AR) antagonist that blocks AR nuclear translocation with K i of 11 nM. Phase 3.TargetsAndrogen receptor 11 nM(Ki)In vitroIn AR-HEK293 cells stably

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of &lt:1 nM, 0.8 nM and 79 nM, respectively.Directly targets wild-type and mutant c-Abl kinase domains.